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A B S T R A C T
We report for the ﬁrst time the isolation of 2-furyl(phenyl)methanol (5) from the chloroform extracts of the
Atractylis gummifera roots. A. gummifera is a thistle belonging to the Asteraceae family that produces the ent-
kaurane diterpenoid glycoside atractyloside (ATR). ATR (1) was isolated and chemically modiﬁed to obtain its
aglycone atractyligenin (2) and the methylated derivatives ATR-OMe (3) and genine-OMe (4). The compounds
1–5 were structurally characterised and evaluated against the intracellular amastigote, cultured within mac-
rophages, and the extracellular promastigote of Leishmania donovani, the protozoan parasite responsible for the
highly infective disease visceral leishmaniasis, which is fatal if untreated. The 2-furyl(phenyl)methanol 5 ex-
hibited notable activity against the promastigote.
1. Introduction
Leishmaniasis (L) is a neglected tropical disease (NTD), aﬀecting 12
million people in almost 90 countries and causing 50,000 deaths each
year [1–3]. Leishmaniasis is generally grouped into three clinical forms,
including cutaneous (CL), mucocutaneous and visceral leishmaniasis
(VL) [4]. CL is the most common variant and, although self-healing, can
create permanent disﬁguring scars [5]. CL is prevalently caused by
Leishmania amazensis, Leishmania major, Leishmania braziliensis, Leish-
mania mexicana and Leishmania panamensi [6]. On the other hand, VL
(also known as kala azar), caused by Leishmania donovani and Leish-
mania infantum, is the most severe form of the infection and, if not
treated, might result in widespread destruction of mucous membranes,
visceral and haemopoetic organs, and ultimately death [7].
Although vaccines against the Leishmania parasites are currently
being developed, the use of chemotherapeutic agents, such as miltefo-
sine, panoromycin and pentavalent antimonials (sodium stibogluconate
and meglumine antimoniate), remains, by far, the most eﬀective
treatment option [1,8–10]. Anti-leishmanial medicines with the ex-
ception of miltefosine are administered intravenously over prolonged
periods of time. The rise of antimonial drug-resistant parasites, decades-
old ﬁrst-line drugs and low patient compliance, due to long drug regi-
mens and unpractical administration routes, has led to high rates of
treatment failure and relapses [7,11].
As a result, there is an urgent need to access and identify novel and
diverse chemical scaﬀolds to support and improve the process of de-
veloping novel anti-leishmanial medicines. To this end, natural pro-
ducts continue to be a remarkable source of therapeutic leads [12] and
tripterpenoids and ent-kaurane diterpenoid glycosides, commonly iso-
lated from some Asteraceae and Annonaceae species, were shown to be
active in vitro against trypanosomatids, such as Trypanosoma cruzi and
T. brucei [13–15].
This ﬁnding prompted us to evaluate against protozoan parasites of
the genus Leishmania (also belonging to the Trypanosomatida order)
both aqueous and chloroform extracts of Atractylis gummifera, a thistle
belonging to the Asteraceae family that grows throughout the
Mediterranean region and is widely known for its acute toxicity [16].
The A. gummifera rhizome contains atractyloside 1 (ATR), a glucoside
consisting of the tetracyclic ent-kaurane diterpene atractyligenin 2 at-
tached through a β-linkage to the anomeric carbon of a D-(+)-glucose
residue (Fig. 1) [17]. ATR exerts its biological activity by inhibiting the
oxidative phosphorylation in the mitochondria of hepatocytes and
proximal tubular epithelial cells, and has been extensively investigated
for its pharmacological and chemical properties [18–20].
To our knowledge, A. gummifera metabolites have not been tested to
date against Leishmania parasites and here we wish to report on the
isolation, characterisation and anti-leishmanial activity of known plant
active principles atractyloside (1) and atractyligenin (2), their methy-
lated derivatives ATR-OMe (3) and atractyligenin-OMe (4), and 2-furyl
(phenyl)methanol (5) that was found in the thistle rhizome's
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chloroform extracts (Fig. 1). The compounds structures were estab-
lished on the basis of spectroscopic methods, including 1D- and 2D-
NMR techniques (1H- and 13C-NMR spectra and COSY, HSQC, NOESY
and HMBC experiments) and high-resolution mass spectrometry
(HRMS). The luciferase assay was used to screen the compounds (1–5)
against the two structural variants of Leishmania donovani, i.e., the
amastigote non-motile form, which is found in the mononuclear pha-
gocytes and circulatory systems of humans, and the promastigote (ex-
tracellular and motile) form, which is found in the alimentary tract of
sand ﬂies [21].
2. Results and discussion
2.1. Chemistry
The crushed rhizome of A. gummifera was treated with an aqueous-
acetone solution in order to isolate atractyloside 1 (ATR), according to
published methods [22,23]. ATR was isolated in good yield and its
NMR spectra and MS analysis were in accordance with the literature
data [17]. The aqueous-acetone rhizome mixture was then extracted
with chloroform and the organic fraction was concentrated and sub-
jected to column chromatography over normal phase silica gel and
semi-preparative HPLC to aﬀord 2-furyl(phenyl)methanol 5 as a pale
yellow amorphous solid. The molecular formula of 5 was established as
C11H10O2 by HR-ESI-MS, which showed the quasi molecular ion peak
[M+H]+ at m/z 175.0755 (calculated for 174.0681). The IR spectrum
showed absorptions for hydroxyl and aromatic (mono-substituted)
groups at 3366 and 749 cm−1, respectively.
The 1H-NMR spectrum of 5 displayed characteristic up-ﬁeld protons
of a mono-substituted benzene ring at δH 7.49 (d, J=7.4 Hz, H-8, H-
12), 7.38 (t, J=7.5 Hz, H-9, H-11) and 7.32–7.30 (m, H-10) (Table 1).
The most up-ﬁeld singlet at δH 7.71 (d, J=1.3 Hz, H-5) correlated with
signals at δH 6.54 (dd, J=3.3, 1.8 Hz, H-4) and 6.78 (d, J=3.3 Hz, H-
3) in 1H-1H COSY and NOESY experiments, and this was indicative of a
2-substituted furan ring.
One signal observed at δH 5,64 (d, J=4.4 Hz, H-6), which HSBC
correlated with δC 62.8, suggested the presence of an oxygenated sp3
methine bridge connecting the phenyl group with the furan ring. The
complete linkage of the phenyl ring and its connection with the furan
moiety via the methane bridge was resolved by the key HMBC corre-
lations from H-6 (δH 5,64) to C-8/12 (δC 126.4), C-7 (δC 135.7) and C-2
(δC 141.5), from H-3 (δH 6.78) to C-4 (δC 111.4) and C-5 (144.8), and
from H-9/11 (δH 7.38) to C-8/12 (δC 126.4) and C-10 (δC 127.8)
(Fig. 2).
Fig. 1. Structures of atractyloside (1), its aglycone atractyligenin (2), their methyl ester derivates 3 and 4, and the 2-furyl(phenyl)methanol (5), which was isolated
from the CHCl3 extracts of A. gummifera roots. Furamidine (DB75) is a pentamidine analogue bearing a core 2,5 disubstituted furan ring.
Table 1
1H- and 13C-NMR data for compounds 5a.
Position δH (J in Hz) δC
2 – 141.5
3 6.78 d (3.3), 1H 115.6
4 6.54 dd (3.3, 1.8) 111.4
5 7.71 d (1.3) 144.8
6 5.64 d (4.4) 62.8
7 – 135.7
8/12 7.49 d (7.4) 2H 126.4
9/11 7.38 t (7.5) 2H 128.4
10 7.32–7.30m 1H 127.8
a Recorded in DMSO-d6, 600 and 125MHz.
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2.2. Biology
Compounds 1–5 were tested for cytotoxicity against transgenic
ﬁreﬂy luciferase-expressing Leishmania donovani amastigote and pro-
mastigote, and bone marrow-derived macrophages from Balb/C mice.
ATR 1, its derivatives 2–4 and the crude chloroform extracts of A.
gummifera were incubated at diﬀerent concentrations (0.001–10mM)
with L. donovani promastigote and amastigote, cultured intracellularly
within macrophages, for 72 h (Fig. 3). Residual ATP levels, or luciferase
activity, against exogenous luciferin (0.1 μg/mL) were determined
using a luminometer and the viability of L. donovani, expressed as
percent of the no-drug control experiments, was subsequently derived.
Atractyloside 1 and its genine 2 did not exhibit any anti-leishmanial or
cytotoxic activity against macrophages, conversely, they appeared to
stimulate the growth of the parasites in a dose-dependent fashion as
illustrated in Fig. 3a (open squares, red lines). However, their methyl
carboxylate derivatives 3 and 4 were found to inhibit the growth of L.
donovani promastigote with IC50 (the dose that kills 50% of cells) values
of 5mM and 0.23mM, respectively (Table 2). Interestingly, the crude
rhizome chloroform extracts showed anti-leishmanial activity with
growth inhibitory concentrations of 0.059 and 0.88mM against the
promastigote and amastigote forms, respectively (Table 2). This notable
ﬁnding prompted us to analyse the composition of the chloroform ex-
tracts of the plant root and 2-furyl(phenyl)methanol 5 was identiﬁed as
the chemical agent responsible for anti-parasitic activity. The newly
isolated compound 5 was retested on its own and showed remarkable
activity against the L. donovani promastigote (0.029mM), with rela-
tively low toxicity against macrophages and high selectivity index
(SI= 345). Compound 5 retained biological activity, albeit at high
concentration, also against the amastigote form of the parasite at 1mM
(SI= 10).
Chiral chromatography analysis of the 2-furyl(phenyl)methanol 5
isolated from the chloroform extract of the A. gummifera rhizome re-
vealed the presence of two enantiomers. The conﬁguration of the ste-
reoisomers was assigned by comparing the HPLC elution order with
previously reported data [24]. The ﬁrst peak, which eluted at 25.4min,
Fig. 2. Key HMBC (in red) and COSY (in bold) correlations of 5. (For inter-
pretation of the references to colour in this ﬁgure legend, the reader is referred
to the web version of this article.)
Fig. 3. a-b. Dose response curves. a) Eﬀects of ATR (1) / ATR-OMe (3) and genin (2) / genin-OMe (4) on L. donovani promastigotes growth. ATR 1 and genin 2 are
shown as open squares, whereas methylated compounds (3 and 4) are shown as ﬁlled squares. b) Eﬀect of 2-furyl(phenyl)methanol 5 on promastigotes (ﬁlled
squares, black line) and amastigotes (open squares, red line). The Y-axis reports the % growth inhibition and X-axis the concentration of the compounds used in this
study. Concentrations are in mM and % inhibition was determined using the luciferase assay protocol previously described [29].
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was identiﬁed as the R enantiomer, whereas the second peak with a
retention time of 30.4 min corresponded to the S enantiomer.
The 2-furyl(phenyl)methanol (5) exhibited moderate activity
against L. donovani amastigote but was 30-fold more active against the
promastigote form of the parasite (29 μM). The phenyl-furan scaﬀold is
particularly rare in natural product frameworks and there are only few
examples reported in the literature of secondary metabolites from
plants and fungi containing this bis-aromatic unit. These include, but
are not limited to, peplidiforone C (6) [25] from Hypericum peplidifo-
lium, 3-hydroxy-1,4,7-trimethoxydibenzofuran (7) [26] from Hypericum
revolutum ssp. and myrothecol (8) [27], a polyketide isolated from the
fungus Myrothecium sp. GS-17 (Fig. 4). The latter (8), which contains a
1,3-dihydroisobenzofuran unit linked to a 2-furyl moiety, is closely
related to the structure of the 2-furyl(phenyl)methanol (5) isolated
from the chloroform fraction of A. gummifera. As a result, we postulate
that 5 might be of polyketide biosynthetic origin with a pathway in-
volving prenylation of a benzene substrate followed oxidation and
synthase-mediated cyclisation via Michael addition mechanisms.
On the other hand, the phenyl-furan moiety is a privileged chemical
scaﬀold present in the structure of a number of synthetic medicinal
compound. For example, furamidine (DB75) [28] is a pentamidine
analogue bearing a core 2,5-disubstitued furan ring, which was eval-
uated in phase III clinical trials for Human African trypanosomiasis
(Fig. 1). As a result, further chemical modiﬁcations can be carried to the
easily accessible 2-furyl(phenyl)methanol in order to furnish attractive
anti-leishmanial chemical probes.
3. Materials and methods
3.1. Experimental section
3.1.1. General experimental information
1H- and 13C-NMR spectra were acquired using Bruker Avance
400MHz and Avance III 600MHz NMR spectrometers. Chemical shifts
are reported in parts per million (ppm) with the solvent resonance as
the internal standard and coupling constants (J) are quoted in Hertz
(Hz). Spin multiplicities are described as s (singlet), bs (broad singlet), d
(doublet), dd (doublet of doublets), t (triplet), q (quadruplet), and m
(multiplet). Optical rotations were determined on a Bellingham and
Stanley digital polarimeter ADP 410.
Infrared spectra were acquired on a Perkin Elmer FT-IR
Spectrometer (Spectrum 1000) and absorbance frequencies are re-
ported in reciprocal centimeters (cm−1).
LC-MS analysis was conducted on an Agilent 6100 series
Quadrupole LC-MS system coupled with a G4220A 1290 binary pump/
DAD, using an Agilent Zorbax SB-C19 reverse-phase column
(2.1× 50mm) with a ﬂow rate of 1mLmin−1. Solution B was kept at
5% for 0.8min, then a gradient was applied up to 100% B at 6.6 min
and solution B was held at 100% for 1.6 min, then B was reverted back
to 5% until 10min. Eluent A: H2O/0.1% formic acid; eluent B: CH3CN/
0.1% formic acid.
HR-MS data were recorded on Thermo LTQ Orbitrap coupled to an
HPLC system (PDA detector, PDA autosampler, and pump). The fol-
lowing conditions were used: capillary voltage of 45 V, capillary tem-
perature of 260 °C, auxiliary gas ﬂow rate of 10–20 arbitrary units,
sheath gas ﬂow rate of 40–50 arbitrary units, spray voltage of 4.5 kV,
and mass range of 100–2000 amu (maximal resolution of 30,000). For
LC/MS, a Sunﬁre C18 analytical HPLC column (5 μm,
4.6 mm×150mm) was used with a mobile phase of 0 to 100% MeOH
over 30min at a ﬂow rate of 1mLmin−1.
Chiral HPLC analysis was performed using a Daicel Chiralcel OD
analytical column (250×4.6mm, 10 μm) and UV detection was
monitored at 230 nm.
TLC and preparative TLC were performed on Merck Silicagel 60 F254
aluminum sheets. TLC system 1: Si gel, EtOAc:acetone:H2O:HOAc /
5:3:1:1, sprayed with a vanillin-H2SO4 solution prepared by dissolving
15 g of vanillin in 250mL of EtOH with 0.01% conc H2SO4. TLC system
2: Si gel, hexane: EtOAc / 9:1. TLC system 3: Si gel, CHCl3:MeOH:HOAc
/ 8:2:0.5.
Puriﬁcations of the intermediates and ﬁnal products were
Table 2
Anti-leishmanial activity of A. gummifera metabolite ATR (1), genin 2, methylated derivatives ATR-OMe (3) and atractyligenin-OMe (4), and 2-furyl(phenyl)me-
thanol (5).
Cytotoxicity IC50 (mM)a
Compound Promastigotes Amastigotes Macrophagesb SIpromastigotec SIamastigoted
ATR (1) N/Ae N/A N/A – –
Genin (2) N/A N/A N/A – –
ATR-OMe (3) 5.18 ± 9.77 N/A N/A – –
Genin-OMe (4) 0.23 ± 0.16 N/A N/A – –
Crude CHCl3 extracts 0.059 ± 0.015 0.88 ± 0.34 > 10 >169 >11
5 0.029 ± 0.006 1.00 ± 1.73 > 10 >345 >10
a IC50 is deﬁned as the dose that kills 50% of cells.
b Bone marrow-derived macrophages from Balb/C mice.
c Selectivity Indexpromastigote= IC50 macrophages/ IC50 promastigotes.
d Selectivity Indexamastigote = IC50 macrophages/IC50 amastigotes.
e N/A – No activity at 10mM. The experiments were carried out in triplicate.
Fig. 4. Chemical structures of natural products bearing phenyl-furan moieties, including peplidiforone C (6), 3-hydroxy-1,4,7-trimethoxydibenzofuran (7) and
myrothecol (8) isolated from Hypericum peplidifolium, Hypericum revolutum ssp. and the fungus Myrothecium sp. GS-17, respectively.
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conducted using an Interchim puriﬂash 4100 automatic puriﬁcation
machine. The crude compounds were injected into the system at a rate
of 250mL/min at 100 bar, using a 15 μg silica, high-capacity columns.
All chemicals were purchased from Fisher Scientiﬁc, Sigma Aldrich
and Merck Chemicals, and used without further puriﬁcation.
3.1.2. Plant material
The A. gummifera rhizomes were identiﬁed through morphological
analysis and collected on 19/03/2014 by Professor Francesco Maria
Raimondo in Piana degli Albanesi, Loc. Maganoce, Palermo, Italy. Fresh
rhizomes were shipped to UK and stored at −20 °C.
3.1.3. Extraction and isolation
The A. gummifera rhizomes (439.64 g) were cut and blended to
obtain a coarse powder, which was initially extracted (1 L/100 g) with
acetone at 40 °C for 2 h. The powdered roots were further extracted
three times with an acetone:water (9:1) mixture (0.5 L/100 g) for 1 h
each time. The four fractions were combined and evaporated under
reduced pressure at a temperature below 40 °C and condensed to
350mL to give a dark-green oily residue, which was extracted with
CHCl3 (3 × 500mL and 1 × 150mL). The organic fractions were
combined, ﬁltered and evaporated at a reduced pressure to yield a
brown oil (1.052 g), which was analysed to identify novel secondary
metabolites.
3.1.3.1. Aqueous phase. The aqueous phase was concentrated to
500mL at a reduced pressure at 40 °C. A 20% aqueous solution of
KCl (100mL) was then added and a white precipitate, containing ATR,
was ﬁltered oﬀ and washed with cold water. The mother solution was
kept a 0–4 °C overnight and more precipitate was formed. A total of
3.750 g of ATR 1 (0.85% yield) was recovered as a pale yellow solid,
which was characterised by TLC (Rf=0.45, purple, TLC system 1), LC-
MS and 1H-NMR spectroscopy. NMR spectral data were identical to
previously analysed pure sample of ATR [17].
3.1.3.2. Organic solvent phase. The brown oil (1.052 g) was subjected to
column chromatography over silica gel column with 0.5% MeOH in
CHCl3 to yield four fractions Fr. 1–4. Further puriﬁcation of Fr 3
(46mg) by preparative TLC (hexane:ethyl acetate - 9.5:0.5) allowed the
isolation of pure 5 (Rf = 0.29, TLC system 2) as a pale yellow solid
(3.5 mg).
3.1.4. Synthetic procedures
The physical and spectral data of compounds 1 were identical to
those of pure samples previously isolated [17]. Compounds 2, 3 and 4
were prepared according to published procedures and their physical
and spectroscopic data agreed with those reported in the literature
[22].
Hydrolysis of ATR 1 to give atractyligenin 2. A solution of 500mg of
ATR (1) in 20% KOH in water (5 mL) was heated under reﬂux for 8 h.
The solution was acidiﬁed with 20% HCl to pH=4 at 0 °C and the
solvent evaporated under reduced pressure. The residue was puriﬁed by
column ﬂash chromatography over silica gel to give 187mg (94% yield)
of pure genin 2 (Rf = 0.17, TLC system 3) as a white solid. [α]20D-145
(c 0.2, EtOH); ESIMS m/z (negative mode) 319 [M−H]−.
General procedure for the synthesis of3and4. To a solution of the de-
sired compound (1 and 2) in a mixture of dry THF:MeOH / 5:3 (8mL)
was added TMSCHN2 (1.5 equiv., 2 M in Et2O) dissolved in dry MeOH
(0.5 mL) at−40 °C over 5min. The reaction was allowed to reach room
temperature and react for 4 h. The reaction mixture was ﬁltered oﬀ
through a silica pad and eluted with MeOH (15mL) to give the desired
product (3 and 4) that were judged pure by analysis of TLC, LC-MS,
NMR, and IR spectra.
Atractyloside methyl ester (ATR-OMe) 3. Starting from 220mg
(0.303mmol) of ATR (1), 197mg (0.266) of 3 were obtained as a pale
yellow solid (88% yield).
Atractyligenin methyl ester (genin-OMe) 4. Starting from 130mg
(0.406mmol) of atractyligenin 2, 110mg (0.329mmol) of 4 were ob-
tained as a white amorphous solid (81% yield). Rf = 0.32, purple,
(TLC=20% MeOH in CHCl3, stained with vanillin-H2SO4 solution).
[α]20D-141 (c 0.2, EtOH); ESIMS m/z (negative mode) 333 [M−H]−.
1H-NMR (600MHz, MeOD) δH 5.18 (bs, 1H, H-17α), 5.08 (bs, 1H, H-
17α), 3.97 (bs, 1H, H-2), 3.77 (bs, 1H, H-15), 3.65 (s, 3H, OCH3), 2.71
(bs, 1H, H-13), 2.65–2.49 (m, 1H, H-4).
2-furyl(phenyl)methanol5. IR νmax (golden gate) cm−1 3366, 2925,
2853, 1641, 1455, 1210, 1032, 969, 749. 1H-NMR and 13C-NMR
(DMSO-d6) please refer to Table 1; ESIMS m/z (positive mode) 175.01
[M+H]+; HRMS calculated for C11H10O2 174.0681, found 175.0755
[M+H]+. Chiral HPLC (Chiralcel OD, 2% isopropanol in hexane, ﬂow
rate= 1mLmin−1, λ=230 nm): RtR=25.4 min for enantiomer S and
RtR=30.4 min for enantiomer R. The conﬁguration of the enantiomers
was assigned by comparing the HPLC elution order with previously
published data [24].
4. Biology
4.1. Parasite lines and cell culture microorganisms and growth conditions
Luciferase-expressing transgenic Leishmania donovani LV82 pro-
mastigotes and amastigotes, within macrophage derived from bone
marrow, were cultured in M199 and RPMI1640 medium (Gibco©),
supplemented with 20% v/v heat-inactivated foetal calf serum (FCS)
(Gibco©), and 1% penicillin streptomycin (Pen/Strep; Gibco ©) at
25 °C [29].
Amastigotes of these lines were cultured within macrophage derived
from bone marrow. The bone marrow derived macrophage were ex-
tracted as non-diﬀerentiated monocytes from bone marrow of the
femur, cultured in Dulbecco's modiﬁed eagle medium (DMEM,
Invitrogen) supplemented with 10% v/v FCS, 1% pen/strep, 30% v/v
cell supernatant and 1% L-glutamine for 7–10 days, after which they
were transferred to RPMI 1640 medium supplemented with 10% FCS
(v/v), 1% pen/strep (v/v) and L-glutamine. Viability of macrophage
was determined with the Trypan blue assay [29] prior to use for in vitro
luminescence assay of intramacrophage amastigotes.
4.2. In vitro Luminescence assay
The previously reported luciferase assay [30] was used to estimate
the cytotoxic eﬀect of the compounds used in this study against trans-
genic L. donovani promastigotes and amastigotes. For promastigotes,
the assay was carried in a 96 well format and 1×106 log phase pro-
mastigotes, with or without drugs at a concentration determined by the
experimental protocol in a ﬁnal volume of 100 μL, were incubated for
72 h at 26 °C. The cell viability was estimated by adding 0.5 μg/mL of
luciferine to the assay plate and the luminescence was measured with
the IVIS bio-imaging platform. Luminescence of drug-treated wells re-
lative to their no drug control expressed as a percentage was used as a
measure of cell viability.
For amastigotes, 105 activated bone derived macrophages were in-
cubated for 24 h in a 96 well plate at 37 °C, 5% CO₂ to adhere to the
bottom of the well. Subsequently, the macrophages were infected with
promastigotes at a ratio promastigotes:macrophage of 20:1, and in-
cubated further for 24 h to allow phagocytosis of the parasites. After the
extracellular parasites were washed out, the drugs were added to the
wells at concentrations determined by the experimental protocol for
72 h, and the viability was estimated as described for promastigotes.
The data presented are derived from independent experiments done in
triplicate. Dose response curves were used to estimate the IC50.
5. Macrophage cellular toxicity
The IC50 of macrophage for the compounds used in this study was
S. Deiva, et al. Fitoterapia 140 (2020) 104420
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estimated using the alamar blue assay. Brieﬂy, macrophages (10 [5])
were incubated with diﬀerent concentrations on drugs determined by
the experimental protocol for 72 h. Viability was estimated by adding
alamar blue and incubating the macrophages further for 6 h. Absor-
bance readings at 595 nm and 570 nm were used to estimate cell via-
bility as described for promastigotes. Dose response curves were used to
estimate the IC50. The selectivity indices were estimated by expressing
the IC50 of macrophages to IC50 on L. donovani amastigotes in-
tracellularly within macrophage or IC50 of promastigotes.
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